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ABSTRACT 
 
Ageing is associated with increased prevalences of both atrial and ventricular arrhythmias, 
reflecting disruption of the normal sequence of ion channel activation and inactivation 
generating the propagated cardiac action potential. Experimental models with specific ion 
channel genetic modifications have helped clarify the interacting functional roles of ion 
channels and how their dysregulation contributes to arrhythmogenic processes at the cellular 
and systems level. They have also investigated interactions between these ion channel 
abnormalities and age-related processes in producing arrhythmic tendency. Previous reviews 
have explored the relationships between age and loss-of-function Nav1.5 mutations in 
producing arrhythmogenicity. The present review now explores complementary relationships 
arising from gain-of-function Nav1.5 mutations associated with long QT3 (LQTS3). LQTS3 
patients show increased risks of life-threatening ventricular arrhythmias particularly after 40 
years of age consistent with such interactions between the ion channel abnormailities and 
ageing. In turn clinical evidence suggests that ageing is accompanied by structural, 
particularly fibrotic, as well as electrophysiological change. These abnormalities may result 
from biochemical changes producing low-grade inflammation resulting from increased 
production of reactive oxygen species and superoxide. Experimental studies offer further 
insights into the underlying mechanisms underlying these phenotypes. Thus, studies in 
genetically modified murine models for LQTS implicated action potential recovery processes 
in arrhythmogenesis resulting from functional ion channel abnormalities. In addition, ageing 
WT murine models demonstrated both ion channel alterations and fibrotic changes with 
ageing. Murine models then suggested evidence for interactions between ageing and ion 
channel mutations and provided insights into potential arrhythmic mechanisms inviting future 
exploration.  
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1. Ageing and the incidence of cardiac arrhythmias 
Ageing refers to the normally occurring, physiological degeneration that causes a persistent 
and progressive decline in the fitness of an organism with time.
1
 This changing biological 
background increases the prevalence of a wide range of clinical conditions with age. Of these, 
cardiovascular disease is the leading cause of death in the elderly.
2
 At least some of this 
mortality has been attributed to the progressive deterioration in cellular and tissue function in 
the heart. 
3, 4
 Among other effects, this increases the incidences of cardiac arrhythmias.
5
 
Atrial fibrillation (AF) is the most common form of arrhythmia and results in substantial 
mortality and morbidity.
6
 Its adult prevalence rises from an overall level of ~1-4% to >13% 
in those over age 80 y.
7
 Similarly, the incidence of ventricular arrhythmias potentially 
resulting in sudden cardiac death also increases with age, showing higher male than female 
prevalences that converge by the eighth decade of life.
8
  
 
Arrhythmic phenomena fundamentally arise from a disruption of the complexly interacting 
sequence of ion current activation and inactivation underlying action potential generation and 
propagation through successive regions of the heart. This involves a wide range of specific 
ion channel types and the effects upon them of their associated subunits. These channels 
variously mediate surface membrane sodium (Na
+
), potassium (K
+
), and calcium (Ca
2+
) 
currents, as well as Ca
2+
 fluxes between different intracellular compartments. Much detailed 
work has characterised their biophysical function in individual channels. However, less is 
known about the effects of abnormalities in the expression or properties of particular ion 
channels at the systems level. Nevertheless, alterations in particular genes encoding specific 
ion channels result in well-defined arrhythmic conditions, and thereby provide useful clinical 
insights into how they might produce arrhythmic tendency. These in turn have prompted 
experimental studies then exploring for the underlying mechanisms. Of these, the Brugada 
(BrS) and long QT syndromes (LQTS) affect 35 in 100,000
9
 and 1 in 2500
10
 persons 
respectively. BrS is associated with Nav1.5 haploinsufficiency compromising Na
+
 channel 
activation and the resulting action potential propagation. Previous reviews have explored the 
relationships between ageing, underlying ion channel abnormalities, morphological changes 
and arrhythmic phenotypes in this condition.
11
 The present review goes on to summarise 
corresponding insights in LQTS, which exemplifies abnormal recovery from excitation. 
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2. Ion channel involvement in arrhythmia in LQTS 
LQTS is characterised by prolonged electrocardiographic (ECG) QT intervals reflecting 
increased ventricular action potential durations (APD) and, in some cases, aberrant T-wave 
ECG signatures. This is associated with increased risks of ventricular arrhythmogenesis 
taking the form of episodic polymorphic ventricular tachycardias (VT) or torsades de pointes 
(TdP). These present either as self-terminating syncopal episodes or may further degenerate 
into ventricular fibrillation and/or sudden cardiac death,
12
 which forms the first presenting 
event in approximately 5% of patients.
10
 Clinical studies additionally associated LQTS with 
increased risks of polymorphic atrial tachyarrhythmias. Such tachyarrhythmic episodes are 
observably longer in LQTS patients than other patients with persistent or induced AF, and 
where P wave features take on undulating characteristics. It is thought that the latter periodic 
changes in P wave vector during polymorphic atrial tachyarrhythmias resemble the twisting 
of the QRS axis observed in ventricular TdP, indicating an atrial form of TdP. 
13
 The range of 
congenital LQT1-LQT13 subtypes are each associated with particular mutations that can 
involve >15 genes.
12
 Where these involve loss-of-function mutations they usually concern K
+
  
current expression or function, as in LQT1, LQT2, LQT5, LQT6, LQT7, LQT11 and 
LQT12.
14
 In contrast, gain-of-function mutations associated with LQTS often involve Na
+
 
and Ca
2+
 current function, as in LQT3, LQT8, LQT9 and LQT10.
14
 LQT1, LQT2 and LQT3 
are the most common LQTS variants and account for ~97% of the cases of congenital 
LQTS.
15
 These conditions have additional associations with other arrhythmic syndromes; 
thus sinoatrial node (SAN) dysfunction occurs in patients with both loss- and gain-of-
function SCN5A mutations. 
16, 17
 
3. Pro-arrhythmic changes associated with ageing 
Ageing is itself accompanied by structural and biochemical changes that may themselves 
increase arrhythmic risk. The increased production of reactive oxygen species (ROS) and 
superoxide in cardiac tissue associated with oxidative stress and low-grade inflammation 
promotes fibrotic change.
18-20
 In contrast, Na
+
 channel expression is conserved with age.
21
 
Nevertheless age-related fibrotic changes could disrupt connexin-mediated cell-cell coupling 
or result in fibroblast-cardiomyocyte fusion. These would compromise AP conduction
22
, 
increase the dispersion of repolarisation
23
, and possibly prolong ventricular recovery times.
24-
26
 All these factors can contribute arrhythmic substrate. Thus, normal cardiac ageing is 
accompanied by electrocardiographic increases in both QT dispersion (QTd), reflecting 
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heterogeneities between maximum and minimum QT intervals
24, 28
 and QT interval, 
reflecting the time interval between myocardial depolarisation and repolarisation.
24, 27
 
Arrhythmic risk increases by ~5% for every 10-ms increase in QT interval beyond the upper 
normal limit
29
 and it is also affected by heterogeneity of repolarisation.  
 
4. Clinical insights on the interactions between ageing, gender and LQTS phenotypes 
Several LQTS phenotypes vary with age, potentially providing platforms for exploring the 
effect of age on ion channel properties and their implications for arrhythmic tendency. In 
addition, the genetic abnormalities and age might interact and thereby accentuate any 
morphological phenotypes
30, 31
, as occurs for the fibrotic phenotype associated with 
channelopathies such as BrS.
32
 LQTS3 patients are frequently bradycardic, and this adds to 
the increased atrial and ventricular arrhythmic risks known to be associated with the lower 
heart rates occurring during rest and sleep. LQTS patients show lower ages of onset for AF, 
typically at age 50 ± 14 years.
33, 34
 LQTS, particularly LQTS3, patients show increased risks 
of life-threatening ventricular arrhythmias after 40 years of age that are influenced by 
particular specific factors, such as gender and clinical history.
12, 35
 LQTS3 patients can also 
show long-term changes normally associated with Nav1.5 haplo-insufficiency resulting in 
overlap syndromes that combine both loss (BrS) and Nav1.5 gain-of-function (LQTS3) 
phenotypes. For example, an 8-generation family carrying SCN5A+/1795insD showed 
bradycardia and TdP episodes, characteristic of LQTS3, and ECG ST segment elevation and 
high rates of nocturnal SCD, characteristic of BrS.
36
 In addition to the effects of ageing, 
gender can affect LQTS phenotypes: women show longer QTc intervals than men, increasing 
predisposition to polymorphic ventricular tachycardia 
37, 38
. In LQTS1 and LQTS2, women 
are at higher risk of TdP than men. The gender difference does not appear to apply to LQTS3 
induced arrhythmia. 
39
 Nevertheless, while their prolonged QTc is linked to increased 
arrhythmic incidences, women show a lower likelihood of sudden cardiac death than men, 
especially through their reproductive years. Given these gender-related differences in QTc 
duration, the diagnosis of LQTS is sex specific with QTc durations of >460 ms in females 
and >440 ms in males.
40
 
 
5. Experimental studies of arrhythmic phenotypes  
Experimental studies of arrhythmogenic mechanisms for LQTS and their relationship to 
ageing have employed a range of animal systems each with their own limitations, particularly 
bearing upon the availability or otherwise of genetically modified variants modelling the 
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corresponding human conditions. Primate studies, such as those on female Cynomolgus 
monkeys, demonstrated associations between age and QT prolongation, whether in the 
presence or absence of pharmacological intervention.
41
 Equine wedge preparations confirmed 
central roles for Kv11.1 in repolarisation processes in common with human hearts.
42
 Ageing 
increased QT intervals and susceptibility to E-4031 or terfenadine-induced QT prolongation 
in conscious female guinea pigs
43
, though not to cisapride-induced QT prolongation in 
isolated guinea pig hearts.
44
 Transgenic LQT2 and LQT3 rabbit models have helped clarify 
roles of spatial and temporal dispersions of repolarisation as arrhythmogenic substrates
45
 and 
the effects of potential antiarrhythmic agents, such as free polyunsaturated fatty acids, in 
preventing TdP.
46
 
 
Mice currently provide the main transgenic system for studying cardiac arrhythmias. They 
reproduce at short intervals with relatively brief (~20 day) gestations, facilitating provision of 
aged mice over relatively short time periods.
11
 Mouse and human hearts have anatomically 
similar conducting, sinoatrial and atrioventricular nodes, His-Purkinje systems and 
contracting atrial and ventricular chambers. Similarities in their physiological properties 
include their Na
+
 channel characteristics and their Nav1.5-mediated phase 0 depolarisation 
phases initiating electrophysiological activity. They differ in their >10 times faster resting 
heart rates, smaller L-type Ca
2+
 currents, and differing K
+
 channel contributions to action 
potential recovery.
47-50
 Nevertheless, the murine model has been useful for investigation of 
arrhythmic conditions related to abnormalities in Na
+
 channel characteristics.
51, 52
  
 
6. The murine Scn5a+/∆KPQ system as a model for LQTS3 
The murine Scn5a+/∆KPQ heart has been used to explore arrhythmic mechanisms (Stokoe et 
al., 2007) and the effects upon these of pharmacological interventions, in LQTS3.
53
 
Scn5a+/∆KPQ hearts carry a gain-of-function mutation deleting three conserved amino acids 
(Lys-1505, Pro-1506, Gln-1507) within the Scn5a inactivation domain, disrupting Nav1.5 
inactivation kinetics.
54
 This enhances late sodium currents (INaL), elongating the AP plateau 
and increasing the likelihood of early afterdepolarisation (EAD) phenomena that can 
precipitate TdP episodes.
55, 56
 Isolated, Langendorff-perfused, Scn5a+/∆KPQ ventricles 
recapitulated increased ventricular arrhythmic tendencies and electrophysiological features 
established in clinical LQTS3. They showed prolonged repolarisation time courses 
preferentially affecting epicardial as opposed to endocardial APD. This inverted the 
transmural repolarisation gradients normally observed in wild type (WT) hearts.
57
 There was 
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also a potential mismatch between AP recovery to the resting membrane potential and of the 
recovery of excitability as reflected in the effective refractory periods (ERP), as quantified by 
APD/ERP ratios. This produced a substrate in which triggering by extrasystolic stimulation 
elicited sustained arrhythmia: both extrasystolic stimuli at progressively decreased intervals 
following regular pacing trains and abrupt increases in pacing rate increased arrhythmic 
incidences.
56, 58-60
  Atrial Scn5a+/∆KPQ cardiomyocytes similarly showed prolonged APD 
and frequent EADs rescued by the INaL inhibitor ranolazine
61, 62
, particularly at slow pacing 
rates.
54, 63
  
 
Murine Scn5a+/∆KPQ hearts also recapitulated the clinical pharmacological features of 
clinical LQTS3. Flecainide and quinidine respectively exerted anti- and pro-arrhythmic 
effects in Scn5a+/∆KPQ ventricles. The observed arrhythmogenicity with quinidine 
challenge correlated with accentuated INaL and EAD phenomena that could potentially trigger 
spontaneous arrhythmia. Arrhythmic tendency in murine Scn5a+/∆KPQ ventricles could then 
be accounted for by triggering vents following the appearance of EADs involving 
contributions from altered Ca
2+
 homeostasis, and from substrate sustaining the arrhythmia 
following such triggering. Thus, the dihydropyridine L-type Ca
2+
 channel antagonist 
nifedipine (10 nM - 1µM) decreased the incidences of both EADs and arrhythmias without 
altering APD through inhibiting ICaL but not INa.
57, 64
 The β-adrenoceptor antagonist, 
propranolol, suppressed EADs and reduced epicardial APD whilst suppressing both 
spontaneous and provoked arrhythmias at 100 nM concentrations.
65
 However, whilst 1 mM 
concentrations also eliminated both EADs and spontaneous arrhythmias, it prolonged 
epicardial and reduced endocardial APDs. It also increased the incidences of arrhythmia 
following extrasystolic stimulation.
65
 Clinical studies similarly report that β-adrenoceptor 
antagonism is less effective in suppressing arrhythmia in LQTS3 than in LQTS1 and 
LQTS2.
66
  
 
Finally, resting membrane potential stabilisation by the KATP channel opener nicorandil 
67
 
reduced arrhythmic frequencies provoked by extrasystolic stimuli whilst reducing left 
ventricular (LV) epicardial but not LV endocardial APD in Scn5a+/∆KPQ ventricles. It 
restored the transmural repolarisation gradients to those of normal (WT) hearts. 
68
 Nicorandil 
is similarly antiarrhythmic in clinical LQTS, reducing QT intervals and spatial repolarisation 
gradients.
69-71
 Restitution properties investigated through progressive increases in pacing 
frequency of murine Scn5a+/∆KPQ hearts showed higher diastolic intervals following action 
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potential recovery, DIcrit, at which instabilities in excitation could potentially result in APD 
alternans producing re-entrant substrate, compared to WT. These were further increased by 
quinidine and decreased by flecainide and nicorandil in parallel with their pro-and anti-
arrhythmic effects.
68, 72
 
 
7. Murine models for age-dependent arrhythmogenicity 
Murine hearts similarly model cardiac changes with ageing. Firstly, ageing appears to be 
intrinsically associated with electrophysiological change. Aged mice (≥ 24 months) 
demonstrated 2.6-fold higher frequencies of arrhythmic events.
21
 Surface ECG studies in both 
anaesthetised and ambulant mice and in isolated perfused hearts demonstrated increased PR 
and QT intervals at ≥25 months, reflecting prolonged atrioventricular conduction and 
ventricular repolarisation respectively. Isolated hearts showed prolonged ventricular mean 
APDs. These findings could be explained in terms of reduced expression of voltage-gated K
+
 
currents (Ito, IK,slow1, IK,slow2 and Iss) in LV myocytes despite an increased INaL from old 31–32 
month mice. These findings in turn correlated with reduced Kv1.4 and Kv1.5 but normal 
Nav1.5 expression.
21
 Secondly, aged mice (52 weeks) showed progressive myocardial 
fibrosis, which was reduced by inhibiting the renin-angiotensin-aldosterone system. Chronic 
administration of eplerenone and losartan, whether alone or in combination, reduced both 
interstitial fibrosis in the RV and LV and the occurrence of scattered patches of replacement 
fibrosis, as revealed by Sirius staining for collagen. Ventricular epicardial mapping in 
Langendorff-perfused hearts demonstrated a correspondingly reduced arrhythmic inducibility 
to extrasystolic stimulation and burst pacing that correlated particularly with reductions in the 
patchy fibrosis. This was accompanied by increased RV transverse conduction velocities and 
decreased anisotropic ratio between the transverse and longitudinal velocities.
73
  
 
Atria of aged (24 month) male Kunming mice showed a greater inducibility of AF, and 
longer electrocardiographic P-wave duration and sinus node recovery times, than their 
younger (2 month) counterparts. There were accompanying increased dispersions of 
repolarisation and greater Ito, though unchanged IKur, particularly in the left atrium. Collagen 
estimations suggested an increased fibrotic phenotype,
74
 which might itself exert pro-
arrhythmic actions. Inactivation of murine atrial cardiomyocyte Mkk4 (Mkk4-ACKO) 
increased interstitial fibrosis and transforming growth factor-β1 (TGF-β1) signalling with a 
dysregulation of matrix metalloproteinases, particularly in ageing (1 y) mice compared to 
adult (6 month) and young (3-4 month) littermates. It increased the sensitivity of cultured 
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cardiomyocytes to angiotensin II-induced activation of TGF-β1 signalling. The aged Mkk4-
ACKO mice were more susceptible to atrial tachyarrhythmias than the corresponding Mkk4-
F/F mice. This correlated with observations of slowed and dispersed atrial conduction which 
modelling studies related to arrhythmic effects. Human atrial tissues in AF similarly showed 
Mkk4 downregulation together with increased production of profibrotic molecules compared 
to results from subjects in sinus rhythm.
75
 
 
8. Experimental insights on the interactions between ageing and LQTS phenotypes 
Recent reports suggest that murine hearts may also model interactions between age-related 
electrophysiological and morphological changes and particular genetic alterations in specific 
ion channels related to LQTS. Thus, extrasystolic stimulation experiments demonstrated that 
young (3 month) and adult (5~9 months) Scn5a+/∆KPQ hearts showed no increases in atrial 
arrhythmic tendency compared to WT.
54, 76
 Indeed, with pacing at high stimulus voltages, <9 
month Scn5a+/∆KPQ hearts showed lower incidences of atrial arrhythmic episodes, which 
had shorter durations, than WT following extrasystolic stimulation and burst pacing.
54
 In 
contrast, arrhythmic tendencies in aged (12 month) Scn5a+/∆KPQ mice were greater than in 
either young or aged WT mice.
76
 These findings correlated with the following differences 
between experimental groups. (1) Regularly paced Scn5a+/∆KPQ hearts showed longer atrial 
APDs and P wave durations than WT hearts, and this difference increased with age.
54, 76
 (2) 
Young WT and young Scn5a+/∆KPQ showed similar AERPs, whereas aged WT but not 
aged Scn5a+/∆KPQ showed increased AERPs. (3) In consequence, aged Scn5a+/∆KPQ 
showed the greatest APD/AERP ratios potentially resulting in arrhythmic substrate. (4) These 
findings were consistent with the greater Nav1.5 expression in young Scn5a+/∆KPQ than 
young WT. (5) Nav1.5 expression then increased with age in the WT but not the 
Scn5a+/∆KPQ.
76
   
 
Scn5a+/∆KPQ mice also showed compromised pacemaker activity, reflected in frequent 
episodes of sinus bradycardia, sinus pause/arrest, and longer sinus node recovery times. 
These phenotypic characteristics resemble those seen in sick sinus syndrome (SSS), which 
can occur at any age but is commonly associated with the elderly.
77
 Additionally, these 
findings were associated with electrocardiographic evidence for depressed intra-atrial, 
atrioventricular node, and intraventricular conduction. These findings were corroborated in 
isolated Scn5a+/∆KPQ sinoatrial preparations which, compared to wild-type preparations, 
showed reduced intrinsic heart rates and slower conduction from the SAN to surrounding 
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atrium. Computer simulations of single SAN cells and two-dimensional SAN-atrial models 
attributed these findings to a combination of augmented INaL and reduced total INa.
78
  
 
Comparable changes resulting in a similar overlap syndrome occur in murine 
Scn5a+/1795insD hearts which combine increased QTc intervals with slowed ventricular 
conduction similarly attributable to reduced INa. ECG studies revealed reduced sinus rates, 
bradycardic pauses that could exceed 500 ms and increased PQ intervals and QRS durations. 
Patch-clamped ventricular Scn5a+/1795insD myocytes showed action potential prolongation 
and increased INaL despite normal voltage-dependent Nav1.5 activation, steady-state rapid or 
slow inactivation properties and recovery from inactivation, with the expected action 
potential prolongation. However, they also exhibited evidence for Nav1.5 deficiency in the 
form of marked (~40%) reductions in peak INa and rate of rise of their action potentials 
(dV/dt)max. Epicardial multi-electrode array recordings in Langendorff-perfused 
Scn5a+/1795insD hearts confirmed a slowed conduction of excitation.
79
  
 
Finally, recent studies associated a development of fibrotic change with LQTS3. The 
characteristics of murine F1759A-dTG atria aged between 4-12 weeks were consistent with 
an altered genotype affecting the fibrotic process itself. The mutation was associated with 
clinical AF. The murine hearts showed an incomplete Nav1.5 inactivation increasing INaL and 
resulting in a prolonged APD and prolonged episodes of spontaneous AF that demonstrated 
atrial rotors, waves and wavelets resembling AF. There was an accompanying fibrosis, 
myofibril disarray, mitochondrial dysfunction and atrial and ventricular enlargement. 
80
 The 
relationship between pacemaker dysfunction and the observed phenotypic characteristics has 
been largely attributed to INaL and INa with no reference made to the funny current (If). It is 
possible that with ageing the observed phenotypic changes may additionally be attributable to 
If in LQTS3. A study exploring the effects of ageing on If suggest that there is reduced atrial 
mRNA and protein expression of the hyperpolarisation-activated cyclic nucleotide-gated 
channel (HCN) isoforms HCN2 and HCN4 in aged dogs.
81
 
 
9. Conclusions 
Arrhythmias result from disruptions in the orderly process of ion channel activation and 
inactivation underlying the action potential initiation and propagation through cardiac tissue. 
The ion channelopathies related to LQTS have provided useful illustrative examples that have 
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facilitated our understanding of the roles that ion channels abnormalities have in 
arrhythmogenic processes. As summarised in Figure 1, we review the physiological 
background underlying the increased incidence of atrial and ventricular arrhythmias with age 
in a gain-of-function Na
+
 channel mutation attributable to LQTS3. This demonstrates how 
cardiac ageing and a gain-of-function mutation converge to exert differing and interacting 
mechanisms, which lead to both trigger and substrate components for arrhythmogenesis. 
Clinical studies have also clarified the background of structural, particularly fibrotic, as well 
as the biochemical and electrophysiological changes that occur with ageing. The mechanisms 
by which such changes exert pro-arrhythmic effects have been clarified by experimental 
studies which suggest both alterations in recovery and activation properties of the heart. It 
was possible to enumerate physiological changes occurring in genetically modified murine 
models for LQTS, in particular LQTS3, and the physiological and fibrotic changes in ageing 
WT, as well as to explore examples where these changes might interact. This provides 
possible directions for exploring the relationship between age-related changes and 
arrhythmia. Furthermore, though not exclusive to cardiac channelopathies, an increasing 
ageing population necessitates explorations of the relationship between age-related changes 
and choices of clinical therapeutic interventions. Presently there is a paucity of scientific 
evidence as to how ageing influences the effectiveness of therapeutic interventions and their 
related complications, specifically in LQTS3. The present review provides evidence of how 
cardiac ageing leads to structural and electrophysiological remodelling of ion channels. 
Therefore, the age-related remodelling changes could well alter the effects of anti-arrhythmic 
agents targeting ion channels. This may result in age-specific indications for different 
available therapeutic interventions directed at cardiac electrophysiological abnormalities. 
Finally, targeting mechanistic pathways leading to fibrosis and ROS generation associated 
with the ageing process itself, could also contribute to reducing arrhythmic tendency.  
 
Funding information 
KJ is funded by the Fundamental Research Grant Scheme 
(FRGS/2/2014/SKK01/PERDANA/02/1), Ministry of Education, Malaysia and the Research 
Support Fund, Faculty of Health and Medical Science, University of Surrey. KC was funded 
by the Physiological Society, United Kingdom. HV is funded by the Wellcome Trust 
Research Training Fellowship (105727/Z/14/Z) and Sudden Arrhythmic Death Syndrome 
(SADS), UK. SA is funded by a Medical Research Council Research Fellowship 
(MR/M001288/1). AG is funded by the McVeigh Benefaction and Sudden Arrhythmic Death 
Page 11 of 17
cepp@wiley.com
Clinical and Experimental Pharmacology and Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12 
 
Syndrome (SADS), UK. CLHH is funded by the Wellcome Trust, Medical Research Council, 
British Heart Foundation and McVeigh Benefaction.   
Conflicts of interest 
 
None declared 
 
 
REFERENCES 
 
1. Rose MR. Evolutionary Biology of Aging: Oxford University Press; 1994. 
2. Khane RS, Surdi AD, Bhatkar RS. Changes in ECG pattern with advancing age. J Basic Clin 
Physiol Pharmacol. 2011;22(4):97-101. 
3. Hariharan N, Sussman MA. Cardiac aging - Getting to the stem of the problem. J Mol Cell 
Cardiol. 2015;83:32-6. 
4. Lakatta EG. So! What's aging? Is cardiovascular aging a disease? J Mol Cell Cardiol. 
2015;83:1-13. 
5. Mirza M, Strunets A, Shen WK, Jahangir A. Mechanisms of arrhythmias and conduction 
disorders in older adults. Clin Geriatr Med. 2012;28(4):555-73. 
6. Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J. 
2000;27(3):257-67. 
7. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 
2014;11(11):639-54. 
8. Josephson ME. Sudden cardiac arrest. Indian Heart J. 2014;66 Suppl 1:S2-3. 
9. Campuzano O, Beltran-Alvarez P, Iglesias A, Scornik F, Perez G, Brugada R. Genetics and 
cardiac channelopathies. Genet Med. 2010;12(5):260-7. 
10. Tester DJ, Ackerman MJ. The molecular autopsy: should the evaluation continue after the 
funeral? Pediatr Cardiol. 2012;33(3):461-70. 
11. Jeevaratnam K, Guzadhur L, Goh YM, Grace AA, Huang CL. Sodium channel 
haploinsufficiency and structural change in ventricular arrhythmogenesis. Acta Physiol (Oxf). 
2016;216(2):186-202. 
12. Alders M, Christiaans I. Long QT Syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace 
SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA)1993. 
13. Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H, et al. Prolonged atrial action 
potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J 
Cardiovasc Electrophysiol. 2003;14(10):1027-33. 
14. Nakano Y, Shimizu W. Genetics of long-QT syndrome. J Hum Genet. 2016;61(1):51-5. 
15. Goldenberg I, Zareba W, Moss AJ. Long QT Syndrome. Curr Probl Cardiol. 2008;33(11):629-
94. 
16. Lei M, Zhang H, Grace AA, Huang CL. SCN5A and sinoatrial node pacemaker function. 
Cardiovasc Res. 2007;74(3):356-65. 
17. Wang Q, Chen Q, Li H, Towbin JA. Molecular genetics of long QT syndrome from genes to 
patients. Curr Opin Cardiol. 1997;12(3):310-20. 
18. Judge S, Jang YM, Smith A, Hagen T, Leeuwenburgh C. Age-associated increases in oxidative 
stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: implications for the 
mitochondrial theory of aging. FASEB J. 2005;19(3):419-21. 
19. Wu J, Xia S, Kalionis B, Wan W, Sun T. The role of oxidative stress and inflammation in 
cardiovascular aging. Biomed Res Int. 2014;2014:615312. 
20. Eghbali M, Eghbali M, Robinson TF, Seifter S, Blumenfeld OO. Collagen accumulation in heart 
ventricles as a function of growth and aging. Cardiovasc Res. 1989;23(8):723-9. 
Page 12 of 17
cepp@wiley.com
Clinical and Experimental Pharmacology and Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
13 
 
21. Signore S, Sorrentino A, Borghetti G, Cannata A, Meo M, Zhou Y, et al. Late Na(+) current and 
protracted electrical recovery are critical determinants of the aging myopathy. Nat Commun. 
2015;6:8803. 
22. de Jong S, van Veen TA, van Rijen HV, de Bakker JM. Fibrosis and cardiac arrhythmias. J 
Cardiovasc Pharmacol. 2011;57(6):630-8. 
23. Rudy Y. Lessons learned about slow discontinuous conduction from models of impulse 
propagation. J Electrocardiol. 2005;38(4 Suppl):52-4. 
24. Yavuz B, Deveci OS, Yavuz BB, Halil M, Aytemir K, Cankurtaran M, et al. QT dispersion 
increases with aging. Ann Noninvasive Electrocardiol. 2006;11(2):127-31. 
25. Turner I, C LHH, Saumarez RC. Numerical simulation of paced electrogram fractionation: 
relating clinical observations to changes in fibrosis and action potential duration. J Cardiovasc 
Electrophysiol. 2005;16(2):151-61. 
26. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT Syndrome: An Emerging Role for 
Inflammation and Immunity. Front Cardiovasc Med. 2015;2:26. 
27. Reardon M, Malik M. QT interval change with age in an overtly healthy older population. Clin 
Cardiol. 1996;19(12):949-52. 
28. De Bacquer D, De Backer G, Kornitzer M. Prevalences of ECG findings in large population 
based samples of men and women. Heart. 2000;84(6):625-33. 
29. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, et al. The long QT 
syndrome. Prospective longitudinal study of 328 families. Circulation. 1991;84(3):1136-44. 
30. Nademanee K, Raju H, de Noronha SV, Papadakis M, Robinson L, Rothery S, et al. Fibrosis, 
Connexin-43, and Conduction Abnormalities in the Brugada Syndrome. J Am Coll Cardiol. 
2015;66(18):1976-86. 
31. Campuzano O, Brugada R. Age, Genetics, and Fibrosis in the Brugada Syndrome. J Am Coll 
Cardiol. 2015;66(18):1987-9. 
32. Matsuo K, Akahoshi M, Nakashima E, Suyama A, Seto S, Hayano M, et al. The prevalence, 
incidence and prognostic value of the Brugada-type electrocardiogram: a population-based study of 
four decades. J Am Coll Cardiol. 2001;38(3):765-70. 
33. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-
onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm. 2008;5(5):704-9. 
34. Darbar D, Kimbrough J, Jawaid A, McCray R, Ritchie MD, Roden DM. Persistent atrial 
fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long 
QT syndrome. J Am Coll Cardiol. 2008;51(8):836-42. 
35. Goldenberg I, Moss AJ, Bradley J, Polonsky S, Peterson DR, McNitt S, et al. Long-QT 
syndrome after age 40. Circulation. 2008;117(17):2192-201. 
36. Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma JW, et al. A 
single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res. 
1999;85(12):1206-13. 
37. Goldberg RJ, Bengtson J, Chen ZY, Anderson KM, Locati E, Levy D. Duration of the QT interval 
and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). 
Am J Cardiol. 1991;67(1):55-8. 
38. Merri M, Benhorin J, Alberti M, Locati E, Moss AJ. Electrocardiographic quantitation of 
ventricular repolarization. Circulation. 1989;80(5):1301-8. 
39. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, et al. Age- and sex-
related differences in clinical manifestations in patients with congenital long-QT syndrome: findings 
from the International LQTS Registry. Circulation. 1998;97(22):2237-44. 
40. American College of Cardiology/American Heart Association Task Force on Clinical Data S, 
Buxton AE, Calkins H, Callans DJ, DiMarco JP, Fisher JD, et al. ACC/AHA/HRS 2006 key data elements 
and definitions for electrophysiological studies and procedures: a report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing 
Committee to Develop Data Standards on Electrophysiology). Circulation. 2006;114(23):2534-70. 
Page 13 of 17
cepp@wiley.com
Clinical and Experimental Pharmacology and Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
 
41. Ishizaka T, Yoshimatsu Y, Ozawa M, Kimotsuki T, Takasaki W, Manabe S, et al. Age-related 
differences of QT interval and autonomic nervous system activity in female cynomolgus monkeys. J 
Pharmacol Toxicol Methods. 2009;60(3):288-95. 
42. Pedersen PJ, Thomsen KB, Olander ER, Hauser F, Tejada Mde L, Poulsen KL, et al. Molecular 
Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether a Go-Go-Related/KCNH2 
Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium. PLoS One. 
2015;10(9):e0138320. 
43. Shiotani M, Harada T, Abe J, Hamada Y, Horii I. Aging-related changes of QT and RR intervals 
in conscious guinea pigs. J Pharmacol Toxicol Methods. 2008;57(1):23-9. 
44. Mittelstadt SW, Adams NA, Spruell RD. Age-dependent effects on cisapride-induced QTc 
prolongation in the isolated guinea pig heart. J Pharmacol Toxicol Methods. 2006;54(2):159-63. 
45. Lang CN, Koren G, Odening KE. Transgenic rabbit models to investigate the cardiac ion 
channel disease long QT syndrome. Prog Biophys Mol Biol. 2016;121(2):142-56. 
46. Milberg P, Frommeyer G, Kleideiter A, Fischer A, Osada N, Breithardt G, et al. Antiarrhythmic 
effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to 
suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of 
repolarization. Heart Rhythm. 2011;8(9):1492-500. 
47. Guo W, Xu H, London B, Nerbonne JM. Molecular basis of transient outward K+ current 
diversity in mouse ventricular myocytes. J Physiol. 1999;521 Pt 3:587-99. 
48. Rentschler S, Vaidya DM, Tamaddon H, Degenhardt K, Sassoon D, Morley GE, et al. 
Visualization and functional characterization of the developing murine cardiac conduction system. 
Development. 2001;128(10):1785-92. 
49. Danik S, Cabo C, Chiello C, Kang S, Wit AL, Coromilas J. Correlation of repolarization of 
ventricular monophasic action potential with ECG in the murine heart. Am J Physiol Heart Circ 
Physiol. 2002;283(1):H372-81. 
50. London B. Cardiac arrhythmias: from (transgenic) mice to men. J Cardiovasc Electrophysiol. 
2001;12(9):1089-91. 
51. Riley G, Syeda F, Kirchhof P, Fabritz L. An introduction to murine models of atrial fibrillation. 
Front Physiol. 2012;3:296. 
52. Killeen MJ, Thomas G, Sabir IN, Grace AA, Huang CL. Mouse models of human arrhythmia 
syndromes. Acta Physiol (Oxf). 2008;192(4):455-69. 
53. Sabir IN, Killeen MJ, Grace AA, Huang CL. Ventricular arrhythmogenesis: insights from 
murine models. Prog Biophys Mol Biol. 2008;98(2-3):208-18. 
54. Dautova Y, Zhang Y, Sabir I, Grace AA, Huang CL. Atrial arrhythmogenesis in wild-type and 
Scn5a+/delta murine hearts modelling LQT3 syndrome. Pflugers Arch. 2009;458(3):443-57. 
55. Belardinelli L, Giles WR, Rajamani S, Karagueuzian HS, Shryock JC. Cardiac late Na(+) current: 
proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and 
oxidative stress. Heart Rhythm. 2015;12(2):440-8. 
56. Head CE, Balasubramaniam R, Thomas G, Goddard CA, Lei M, Colledge WH, et al. Paced 
electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice. J Cardiovasc 
Electrophysiol. 2005;16(12):1329-40. 
57. Thomas G, Gurung IS, Killeen MJ, Hakim P, Goddard CA, Mahaut-Smith MP, et al. Effects of L-
type Ca2+ channel antagonism on ventricular arrhythmogenesis in murine hearts containing a 
modification in the Scn5a gene modelling human long QT syndrome 3. J Physiol. 2007;578(Pt 1):85-
97. 
58. Nuyens D, Stengl M, Dugarmaa S, Rossenbacker T, Compernolle V, Rudy Y, et al. Abrupt rate 
accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 
syndrome. Nat Med. 2001;7(9):1021-7. 
59. Stokoe KS, Balasubramaniam R, Goddard CA, Colledge WH, Grace AA, Huang CL. Effects of 
flecainide and quinidine on arrhythmogenic properties of Scn5a+/- murine hearts modelling the 
Brugada syndrome. J Physiol. 2007;581(Pt 1):255-75. 
Page 14 of 17
cepp@wiley.com
Clinical and Experimental Pharmacology and Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
15 
 
60. Stokoe KS, Thomas G, Goddard CA, Colledge WH, Grace AA, Huang CL. Effects of flecainide 
and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT 
syndrome 3. J Physiol. 2007;578(Pt 1):69-84. 
61. Lemoine MD, Duverger JE, Naud P, Chartier D, Qi XY, Comtois P, et al. Arrhythmogenic left 
atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovasc Res. 
2011;92(1):67-74. 
62. Nagatomo T, January CT, Ye B, Abe H, Nakashima Y, Makielski JC. Rate-dependent QT 
shortening mechanism for the LQT3 deltaKPQ mutant. Cardiovasc Res. 2002;54(3):624-9. 
63. Blana A, Kaese S, Fortmuller L, Laakmann S, Damke D, van Bragt K, et al. Knock-in gain-of-
function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. 
Heart Rhythm. 2010;7(12):1862-9. 
64. Lindegger N, Hagen BM, Marks AR, Lederer WJ, Kass RS. Diastolic transient inward current in 
long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J Mol Cell Cardiol. 
2009;47(2):326-34. 
65. Thomas G, Killeen MJ, Grace AA, Huang CL. Pharmacological separation of early 
afterdepolarizations from arrhythmogenic substrate in DeltaKPQ Scn5a murine hearts modelling 
human long QT 3 syndrome. Acta Physiol (Oxf). 2008;192(4):505-17. 
66. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al. Association of long 
QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 
2004;292(11):1341-4. 
67. Hiraoka M, Fan Z. Activation of ATP-sensitive outward K+ current by nicorandil (2-
nicotinamidoethyl nitrate) in isolated ventricular myocytes. J Pharmacol Exp Ther. 1989;250(1):278-
85. 
68. Hothi SS, Booth SW, Sabir IN, Killeen MJ, Simpson F, Zhang Y, et al. Arrhythmogenic 
substrate and its modification by nicorandil in a murine model of long QT type 3 syndrome. Prog 
Biophys Mol Biol. 2008;98(2-3):267-80. 
69. Aizawa Y, Uchiyama H, Yamaura M, Nakayama T, Arita M. Effects of the ATP-sensitive K 
channel opener nicorandil on the QT interval and the effective refractory period in patients with 
congenital long QT syndrome. Investigator Group for K-Channel Openers and Arrhythmias. J 
Electrocardiol. 1998;31(2):117-23. 
70. Foster MN, Coetzee WA. KATP Channels in the Cardiovascular System. Physiol Rev. 
2016;96(1):177-252. 
71. Shimizu W, Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion 
of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT 
syndrome. Circulation. 2000;102(6):706-12. 
72. Sabir IN, Li LM, Jones VJ, Goddard CA, Grace AA, Huang CL. Criteria for arrhythmogenicity in 
genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT 
syndrome type 3 and the Brugada syndrome. Pflugers Arch. 2008;455(4):637-51. 
73. Stein M, Boulaksil M, Jansen JA, Herold E, Noorman M, Joles JA, et al. Reduction of fibrosis-
related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse 
model. Am J Physiol Heart Circ Physiol. 2010;299(2):H310-21. 
74. Luo T, Chang CX, Zhou X, Gu SK, Jiang TM, Li YM. Characterization of atrial histopathological 
and electrophysiological changes in a mouse model of aging. Int J Mol Med. 2013;31(1):138-46. 
75. Davies L, Jin J, Shen W, Tsui H, Shi Y, Wang Y, et al. Mkk4 is a negative regulator of the 
transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis 
with age. J Am Heart Assoc. 2014;3(2):e000340. 
76. Guzadhur L, Pearcey SM, Duehmke RM, Jeevaratnam K, Hohmann AF, Zhang Y, et al. Atrial 
arrhythmogenicity in aged Scn5a+/DeltaKPQ mice modeling long QT type 3 syndrome and its 
relationship to Na+ channel expression and cardiac conduction. Pflugers Arch. 2010;460(3):593-601. 
77. de Marneffe M, Gregoire JM, Waterschoot P, Kestemont MP. The sinus node function: 
normal and pathological. Eur Heart J. 1993;14(5):649-54. 
Page 15 of 17
cepp@wiley.com
Clinical and Experimental Pharmacology and Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
 
78. Wu J, Zhang Y, Zhang X, Cheng L, Lammers WJ, Grace AA, et al. Altered sinoatrial node 
function and intra-atrial conduction in murine gain-of-function Scn5a+/DeltaKPQ hearts suggest an 
overlap syndrome. Am J Physiol Heart Circ Physiol. 2012;302(7):H1510-23. 
79. Remme CA, Verkerk AO, Nuyens D, van Ginneken AC, van Brunschot S, Belterman CN, et al. 
Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of 
human SCN5A-1795insD. Circulation. 2006;114(24):2584-94. 
80. Wan E, Abrams J, Weinberg RL, Katchman AN, Bayne J, Zakharov SI, et al. Aberrant sodium 
influx causes cardiomyopathy and atrial fibrillation in mice. J Clin Invest. 2016;126(1):112-22. 
81. Li YD, Ji YT, Zhou XH, Jiang T, Hong YF, Li JX, et al. Effects of ivabradine on cardiac 
electrophysiology in dogs with age-related atrial fibrillation. Med Sci Monit. 2015;21:1414-20. 
 
 
 
 
FIGURE LEGEND 
 
Figure 1.  Unified diagram summarising the superimposition of a cardiac ageing 
phenomenon on a gain-of-function SCN5A mutation. An increased production of reactive 
oxygen species is observed with cardiac ageing, causing low-grade inflammation that 
promotes fibrotic change. Experim ntally, a gain-of-function Scn5a mutation has also been 
associated with fibrotic change. Through this fibrotic change, cardiac ageing and a gain-of-
function SCN5A mutation converge on disrupting connexin coupling between myocytes. 
Cardiac ageing additionally leads to increased P wave and QT durations prolonging the 
repolarisation of both the atria and ventricles. Collectively these create substrates for 
arrhythmogenesis. The gain-of-function SCN5A mutation delays channel inactivation, 
resulting in an increased late sodium current, forming a substrate for arrhythmogenesis 
through prolongation of atrial and ventricular repolarisation or forming triggers through the 
promotion of early after depolarisations or sino-atrial node dysfunction. The dotted arrow 
represents a hypothetical possibility that a gain-of-function mutation may accelerate cardiac 
ageing processes, leading to arrhythmic tendencies earlier in life. 
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Figure 1. Unified diagram summarising the superimposition of a cardiac ageing phenomenon on a gain-of-
function SCN5A mutation. An increased production of reactive oxygen species is observed with cardiac 
ageing, causing low-grade inflammation that promotes fibrotic change. Experimentally, a gain-of-function 
Scn5a mutation has also been associated with fibrotic change. Through this fibrotic change, cardiac ageing 
and a gain-of-function SCN5A mutation converge on disrupting connexin coupling between myocytes. 
Cardiac ageing additionally leads to increased P wave and QT durations prolonging the repolarisation of both 
the atria and ventricles. Collectively these create substrates for arrhythmogenesis. The gain-of-function 
SCN5A mutation delays channel inactivation, resulting in an increased late sodium current, forming a 
substrate for arrhythmogenesis through prolongation of atrial and ventricular repolarisation or forming 
triggers through the promotion of early after depolarisations or sino-atrial node dysfunction. The dotted 
arrow represents a hypothetical possibility that a gain-of-function mutation may accelerate cardiac ageing 
 processes, leading to arrhythmic tendencies earlier in life.   
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